Researchers found a way to grow hepatitis C virus in labs, enabling genetic studies and potential vaccine development. The breakthrough could speed up progress against the disease, which affects 170 million worldwide.
Researchers identify gC1qR as a binding partner for Hepatitis C core protein, allowing the virus to evade immune response and persist in the body. The interaction between gC1qR and core protein may provide new targets for developing therapies to combat chronic hepatitis C.
A study led by the National Institutes of Health (NIH) has identified key changes in surface proteins of the hepatitis C virus (HCV) that enable it to evade the immune system. The research found that these changes occur early in the infection process and can determine whether a person will develop chronic or acute HCV disease.
A University of Maryland School of Medicine study found that mass treatment campaigns for schistosomiasis in Egypt led to a significant transmission of hepatitis C. The campaign used reusable needles and syringes, which were later replaced with disposable ones.
Researchers at Chiron Corporation have identified a protein molecule (CD81) that binds to the hepatitis C virus (HCV), providing clues on how the virus infects human cells. This discovery has significant implications for the development of new vaccines and therapeutics to prevent and treat chronic HCV infection.
A collaborative study between the US and Russia aims to uncover the causes of Hepatitis C, a prevalent liver disease. The project will collect blood samples and questionnaires from over 4,000 individuals across New Mexico and Chelyabinsk-70, with results expected to shed new light on the virus.
Researchers at the University of Washington have discovered a potential new target for therapeutic drugs to treat hepatitis C. The study found that a protein called NS5A can bind to and inactivate a key component of interferon response, PKR. This could lead to the development of a new treatment for the disease.